Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer by Deng, G et al.
Methylation of hMLH1 promoter correlates with the gene
silencing with a region-speciﬁc manner in colorectal cancer
G Deng*
,1,2, E Peng
1,2, J Gum
1,2, J Terdiman
1,2, M Sleisenger
1,2 and YS Kim
1,2
1Gastrointestinal Research Laboratory, 151M2 Veteran Affairs Medical Center, University of California, San Francisco, 4150 Clement Street, San Francisco,
California, CA 94121, USA;
2Department of Medicine, University of California, San Francisco, 4150 Clement Street, San Francisco, California, CA 94121, USA
Microsatellite instability is present in over 80% of the hereditary non-polyposis colorectal carcinoma and about 15–20% of the
sporadic cancer. Microsatellite instability is caused by the inactivation of the mismatch repair genes, such as primarily hMLH1,
hMSH2. To study the mechanisms of the inactivation of mismatch repair genes in colorectal cancers, especially the region-
speciﬁc methylation of hMLH1 promoter and its correlation with gene expression, we analysed microsatellite instability,
expression and methylation of hMLH1 and loss of heterozygosity at hMLH1 locus in these samples. Microsatellite instability
was present in 17 of 71 primary tumours of colorectal cancer, including 14 of 39 (36%) mucinous cancer and three of 32
(9%) non-mucinous cancer. Loss of hMLH1 and hMSH2 expression was detected in nine and three of 16 microsatellite
instability tumours respectively. Methylation at CpG sites in a proximal region of hMLH1 promoter was detected in seven of
nine tumours that showed no hMLH1 expression, while no methylation was present in normal mucosa and tumours which
express hMLH1. However, methylation in the distal region was observed in all tissues including normal mucosa and hMLH1
expressing tumours. This observation indicates that methylation of hMLH1 promoter plays an important role in microsatellite
instability with a region-speciﬁc manner in colorectal cancer. Loss of heterozygosity at hMLH1 locus was present in four of 17
cell lines and 16 of 54 tumours with normal hMLH1 status, while loss of heterozygosity was absent in all nine cell lines and
nine tumours with abnormal hMLH1 status (mutation or loss of expression), showing loss of heterozygosity is not frequently
involved in the inactivation of hMLH1 gene in sporadic colorectal cancer.
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As an indicator of a distinctive carcinogenesis pathway, the pheno-
type of microsatellite instability (MSI) is present in over 80% of
the hereditary non-polyposis colorectal carcinoma (HNPCC,
Aaltonen et al, 1993) and approximately 15–20% of sporadic
cancer (Thibodeau et al, 1993). Germline mutation of mismatch
repair (MMR) genes (mainly hMLH1 and hMSH2) are detected
in over 70% of HNPCC patients with MSI (Kane et al, 1997; Papa-
dopoulos and Lindblom, 1997). In tumours with MSI from
patients with no obvious family history, mutations of MMR genes
are rare. However, loss of hMLH1 gene expression (gene silencing)
was frequently observed in these tumours (Thibodeau et al, 1996).
When methylation was analysed by HpaII digestion method or
methylation speciﬁc polymerase chain reaction (MSP) method,
the methylation of CpG sites in the promoter region was generally
consistent with the hMLH1 silencing. However, there were many
exceptions, where methylation was detected in normal expressing
cells (Boyer et al, 1995; Cunningham et al, 1998; Herman et al,
1998; Veigl et al, 1998; Wheeler et al, 1999). In our previous study,
we analysed the methylation status of the hMLH1 promoter by
using NaHSO3-sequencing method. We found that methylation
in a more proximal region of the promoter (bases 7248 to
7178, relative to the transcription start site) was detected in all
colorectal cancer cell lines which lacked gene expression, while in
all expressing cell lines, the methylation was absent. However,
methylation in a more distal region was present in all colorectal
cancer cell lines, including the expressing cell lines (Deng et al,
1999). To examine whether this region-speciﬁc effect in cell lines
also applies to primary tumours and gain a better understanding
of the mechanism of the inactivation of MMR genes in sporadic
colorectal cancer, we ﬁrst evaluated a method, called ‘COBRA’
(Xiong and Laird, 1997), by comparing the methylation status of
hMLH1 promoter in cell lines determined using COBRA with the
NaHSO3-sequencing method. We then used COBRA to analyse
the proximal region and distal region of the hMLH1 promoter in
primary tumours with different expression levels. Since loss of
heterozygosity (LOH) is one of the mechanisms for gene inactiva-
tion, and previous studies have detected LOH at the hMLH1 locus
in HNPCC tumours (Hemminky et al, 1994; Wheeler et al, 2000),
it is important to know whether LOH mediates the inactivation of
hMLH1 in sporadic cancer. Therefore, we also analysed LOH at
hMLH1 locus in these primary colorectal cancers.
MATERIALS AND METHODS
Cell lines
Colorectal cancer cell lines SW1116, HCT8, Colo201, Colo320DM,
CACO2, SW1463, HRT18, HT29, SW620, LS123, LS174T,
HCT116, SW48, Lovo, and H498 were obtained from American
Type Culture Collection (Manassas, VA, USA). Cell lines VACO5,
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kindly provided by Drs Sanford Markowitz and James KV Willson
(Willson et al, 1987; Veigl et al, 1998). Cell lines RW2982 and
RW7213 were from Dr Lance M Tibbetts. Cell lines C1a was
derived from 5583s provided by Dr Fred T Bosman. Cell lines
RKO and C were from Dr Michael Brattain. Cells were grown in
DMEM supplemented with 10% foetal bovine serum at 378C with
5% CO2 atmosphere.
Tissues
Primary tumours were obtained at University of Chicago Hospitals,
at Minneapolis Veteran Affairs Medical Center and at San Francis-
co Veteran Affairs Medical Center. All the 71 tumours were from
patients with no known family history of colorectal cancer meeting
the criteria of HNPCC, including 32 non-mucinous cancer and 39
mucinous cancer. Tumours were microdissected from formalin-
ﬁxed, parafﬁn-embedded histologic sections stained with haema-
toxylin-eosin as described previously (Deng et al, 1996). Normal
mucosa of the same patient was also microdissected from the histo-
logical sections of normal tissue blocks taken at least 5 cm away
from the tumours.
MSI analysis
MSI of the primary tumours was determined by comparing the
polymerase chain reaction (PCR) patterns of tumours with their
normal counterparts ampliﬁed with the polymorphic loci BAT26,
D3S2420, APC, D11S1999 and D18S877. Samples showing differ-
ences between normal and tumour in two or more loci were
scored as MSI. Those showing no difference or difference in only
one locus were scored as microsatellite stable (MSS).
DNA methylation analysis
Methylation status of CpG sites in hMLH1 promoter was deter-
mined by two methods based on the principles that cytidine in
DNA is converted to thymidine when DNA is treated with
NaHSO3, while methylated cytidine is protected from the conver-
sion. Thus, the unmethylated and methylated cytidine can be
distinguished by sequencing or digestion with a restriction enzyme,
which recognizes a sequence containing CpG. The determination of
methylation in hMLH1 promoter with NaHSO3-sequencing meth-
od has been described previously (Deng et al, 1999). In the
present study, we also used NaHSO3-digestion (or COBRA)
method to analyse hMLH1 methylation in cell lines and tumours
(Xiong and Laird, 1997). To determine methylation in the proxi-
mal region of promoter, DNA was treated with NaHSO3, and
ampliﬁed by PCR with primers 5'-TTTTGGTATTTTTGTTTT-
TATTGGT (upstream) and 5'-TCCAACCACCAAATAACCCCTA
(downstream) covering the region from 7322 to +56. PCR
product was digested with restriction enzyme BstUI which recog-
nises CGCG sequence. After electrophoresis on a 2% agarose gel,
the fraction of the digested fragments (92 base pairs (bp) and
286 bp) in the total of the digested and undigested fragment
(378 bp) represented the per cent of methylation in the proximal
region of hMLH1 promoter. For methylation analysis of the prox-
imal region in primary tumours, the similar procedure was carried
out except that another downstream primer (5'-TAAAACAAC-
TACTACCCACTACCTA) was used in PCR, and the undigested
fragment (137 bp) and digested fragments (92 and 45 bp) were
separated on a 6% polyacrylamide gel. To analyse methylation in
the distal region, the NaHSO3 treated DNA was ampliﬁed by
PCR with primers 5'-TTTTAGTTGTGATTTTTTAAGGTT (up-
stream) and 5'-AAAACAATAAAACCCTATACCTAA (down-
stream) covering the region from 7796 to 7547. The PCR
product with 250 bp in length was digested with BstUI, and elec-
trophorised on a 2% agarose gel. The digested fragments (125,
67, 52 and 6 bp) represent the methylation in the distal region
of hMLH1 promoter.
LOH analysis
LOH analysis was performed as described previously (Deng et al,
1996). LOH analysis at hMLH1 locus in primary tumours was
carried out by comparing the electrophoresis pattern of tumour
and normal mucosa from the same patient after PCR with the
primers D3S1768 and D3S2447, which are located at the same locus
as hMLH1 gene. The density of each band representing each allele
was measured with a densitometer. The ratio of densities from two
alleles in tumour sample was normalised by the ratio of densities
from two alleles in normal sample. Tumours with the ratio of
50.5 or 42.0 were scored as LOH. The determination of LOH
in cell lines was performed by analysing the patterns of each cell
line after PCR with six di- and tetra-nucleotide polymorphism
primers D3S2423, D3S2396, D3S1745, D3S1768, D3S2447 and
D3S1611. Since these primers are located less than ﬁve centi-
Morgans from hMLH1 locus, and all of them show a high per cent
of heterozygosity (from 0.58 to 0.87), it is highly unlikely
(P=0.0007) that an individual will have two identical alleles in all
six primers. Thus, sample with one single band after PCR with
all these primers was scored as LOH (Wheeler et al, 1999).
Immunohistochemistry analysis
The labelled avidin-biotin method was applied in the immunohis-
tochemical staining as described (Thibodeau et al, 1996), using
anti-hMLH1 antibody (clone G168-15, PharMingen) and anti-
hMSH2 antibody (clone FE11, Calbiochem). After deparafﬁnisa-
tion, sections were subjected to heat-induced antigen retrieval in
10 mM sodium citrate buffer, pH 6.0 for 20 min. Nonspeciﬁc
protein binding was blocked by incubating sections with 10% goat
serum blocking solution (Zymed Histostain-Plus Kit) for 10 min.
Anti-hMLH1 was applied and incubated at 48C overnight. Sections
were rinsed in PBS followed by incubation of biotinylated second-
ary antibody (Zymed) for 10 min in room temperature. After a
brief rinsing, streptavidin-enzyme conjugate (Zymed) was applied
and incubated for 10 min. Sections were washed, followed by
incubation with diaminobenzidine for 2–3 min. Without counter-
staining, sections were dehydrated in graded ethanol and cleared in
xylene. Staining for hMSH2 was performed as above with the
exception of antigen retrieval incubation for 10 min.
RESULTS
Loss of hMLH1 expression is one of the main causes of MSI
in colorectal cancer
In our previous study, by comparing MSI with the abnormality of
MMR genes in colorectal cancer cell lines, we observed that altera-
tion of hMLH1 gene was the main cause of MSI, and the loss of
expression was more frequently observed than mutations in
hMLH1 inactivation (Deng et al, 1999). In this study, we further
analysed MSI in 71 primary colorectal cancers. MSI was detected
in 17 cases (24%) of all sporadic cancers analysed (Table 1). To
identify the inactivation of MMR genes, we measured hMLH1
and hMSH2 protein expression by immunohistochemical staining
with anti-hMLH1 and anti-hMSH2 antibodies. Figure 1 shows
the immunostaining of primary tumours (B, D, F and H) and their
normal mucosa counterparts (A, C, E and G) from the same color-
ectal cancer patients with hMLH1 antibody (A to D) and hMSH2
antibody (E to H). Normal mucosa was positively stained with
either hMLH1 antibody (A and C) or hMSH2 antibody (E and
G). Tumours in B and F shows negative staining by hMLH1 and
hMSH2 antibodies, respectively, while tumours in D and H were
positively stained by these antibodies. We summarised the
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the 47 stained cancers with MSS, all the samples were positively
stained by both anti-hMLH1 and anti-hMSH2 antibodies. In the
16 stained tumours with MSI, nine showed negative staining with
anti-hMLH1 and positive staining with anti-hMSH2, and three
showed positive with anti-hMLH1 and negative with anti-hMSH2.
The result indicated that lack of hMLH1 or hMSH2 protein expres-
sion is the cause of MSI in most tumours. However, there were
four tumours with MSI that were positively stained with both
anti-hMLH1 and anti-hMSH2 (Table 1). These tumours may have
missense mutations in hMLH1 or hMSH2, which destroy the
normal function of DNA mismatch repair (Wheeler et al, 1999),
or they may have mutations in other MMR genes. This hypothesis
is true in both mucinous and non-mucinous cancers. MSI and
hMLH1, hMSH2 expression were compared in mucinous and
non-mucinous cancer. MSI was present in 14 of 39 (36%) muci-
nous cancer and in only three of 32 (9%) non-mucinous cancer.
Mucinous cancer shows signiﬁcant higher incidence of MSI than
non-mucinous cancer (P50.01 by 262 chi square test). This
observation indicated that mucinous cancer might have different
pathogenic pathway compared with the non-mucinous cancer.
However, we did not observe any signiﬁcant difference in the
hMLH1 and hMSH2 staining between mucinous and non-muci-
nous cancers with MSI. In 13 mucinous unstable cancers, seven
and three cases showed negative hMLH1 and hMSH2 staining
respectively. In three non-mucinous cancers with MSI, two cases
were not stained with hMLH1 antibody (Table 1).
Methylation of CpG sites in a proximal region of hMLH1
promoter, but not the distal region, is consistent with loss
of expression in colorectal cancer
In the previous study, we have shown that methylation in a prox-
imal region of hMLH1 promoter invariably correlates with the
absence of expression in colorectal cancer cell lines (Deng et al,
1999). To study whether this correlation still exists in primary
tumour, we need to analyse the methylation status in primary
tumours with different hMLH1 expression levels. Thus, a simpler
method for analysing methylation, COBRA, was evaluated by
comparing methylation in colorectal cancer cell lines determined
by this method (Figure 2A) with that by NaHSO3-sequencing
(Deng et al, 1999). The methylation status determined by these
two methods were identical. This is not surprising, since the BstUI
site used in COBRA is composed with two consecutive CpG sites
within this proximal region. By using COBRA, we extended the
methylation measurement to 64 primary tumours and mucosa
from the same patients (Figure 2B). No methylation was detected
in normal mucosa from these patients. In 55 anti-hMLH1 antibody
positive tumours, none showed methylation, while in nine anti-
hMLH1 antibody negative tumours, seven showed methylation.
No methylation was found in the other two tumours with negative
staining. These two tumours may represent those expressing a
truncated protein (e.g. from nonsense, frameshift, or splice site
mutations) which can not be recognised by the antibody that
was used. In the previous study, we observed extensive methylation
of CpG sites in Region A of hMLH1 promoter in all colorectal
cancer cell lines regardless of the RNA expression levels (Deng et
al, 1999). To see whether this observation exists in primary
tumours, we measured the methylation in Region A in the primary
tumours and their normal counterparts (Figure 2C). Partial methy-
lation (40–60%) was detected in all normal and tumour tissues
tested, indicating that methylation in only a proximal region, but
not in the distal region, correlates with the loss of expression,
and that hMLH1 silencing by methylation is region speciﬁc.
hMLH1 inactivation is mediated by biallelic methylation of
the promoter or mutation of the gene rather than LOH
LOH at hMLH1 locus was analysed in 26 cell lines. In 17 cell lines
with normal hMLH1 expression and wild type DNA sequence,
four lines (SW1116, Colo201, RW7213 and H498) showed only
a single band at each of the six consecutive polymorphic loci.
We scored these four cell lines as LOH (Table 2), because it is
highly unlikely that these cells lines have two identical alleles in
all six consecutive loci (see Materials and Methods section). In
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Table 1 Comparison of MSI, hMLH1 and hMSH2 expression in muci-
nous and non-mucinous colorectal cancers
Expression
No. of Total hMLH1+ hMLH17 hMLH1+
cases stained hMSH2+ hMSH2+ hMSH27
All cancers
MSS 54 47 47 0 0
MSI 17 16 4 9 3
Total 71 63 51 9 3
Mucinous cancer
MSS 25 18 18 0 0
MSI 14 13 3 7 3
Total 39 31 21 7 3
Non-mucin cancer
MSS 29 29 29 0 0
MSI 3 3 1 2 0
Total 32 32 30 2 0
Figure 1 Immunohistochemical staining of colorectal cancers by
hMLH1and hMSH2 antibodies. Primary tumours (B, D, F and H) and their
normal mucosa counterparts (A, C, E and G) from the same colorectal
cancer patients were immunostained with anti-hMLH1 antibody (A to
D) or anti-hMSH2 antibody (E to H) as described in Materials and
Methods. Bar=160 mm.
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loss of expression, LOH was not detected. Since almost 100%
methylation (Figure 2 and Deng et al, 1999) and non allelic loss
was detected in seven cell lines with the silenced expression
(SW48, VACO5, VACO6, RKO, C, VACO432 and C1a), it is
reasonable to believe that both alleles of hMLH1 promoter are
methylated. This is consistent with the previous observation of
biallelic methylation in VACO5 (Veigl et al, 1998). In the cell line
C1a which shows both mutation and methylation, it is not clear
which event occurs ﬁrst. For the cells with mutations and normal
expression, as in HCT116, the single truncated hMLH1 protein
band (due to the nonsense mutation at codon 252) was ﬁrst
explained by the loss of the wild type allele (Papadopoulos et
al, 1994). However, it was reported later that HCT116 cell
contained two intact chromosome 3 by karyotypic analysis (Koi
et al, 1993). The LOH analysis in this study also proved that
two hMLH1 alleles were present in HCT116 (Table 2). Since
DNA sequencing of HCT116 cell revealed sole and complete
mutation at codon 252, we assumed that HCT116 contained
two identical hMLH1 mutant alleles. A similar possibility also
applies to LS174T cell, since we only observed a complete
missense mutation at codon 117 from reverse transcription–
PCR product (Deng et al, 1999), and no LOH was detected at
the hMLH1 locus (Table 2). The missense mutation at this codon
(codon 117) has been shown to alter normal hMLH1 function by
functional analysis (Shimodaira et al, 1998). Thus, the analysis of
mutation and methylation in nine cell lines with abnormal
hMLH1 showed that loss of the normal function of hMLH1 is
mediated by either biallelic methylation in the promoter in six,
by mutation and methylation in one, and by mutation in two cell
lines. LOH at hMLH1 locus in four of 17 cell lines with normal
hMLH1 status suggests that a tumour suppresser gene may be
present adjacent to hMLH1 locus, which is involved in colorectal
carcinogenesis.
LOH status was also determined in primary tumours, and
compared with the immunostaining by anti-hMLH1 antibody
(Table 3). In 54 tumours with positive staining, LOH was
detected in 16 cases (30%), while in nine tumours with negative
staining, no LOH was found. In the four cell lines (Table 2) and
16 primary tumours with LOH (Table 3), hMLH1 expression was
normal. This indicates that when one allele is deleted, the retained
allele (wild type) can still perform normal function. However,
some other tumour suppressor genes within this region may be
inactivated by two hits, resulting in cancer formation. The obser-
vation that LOH is not present in primary tumours with negative
hMLH1 staining together with the similar observation in cell lines
suggests that biallelic methylation or mutation, but not LOH, are
the causes of the inactivation of hMLH1 in cell lines and primary
tumours of sporadic colorectal cancer patients with MSI. In the
hMLH1 positive staining tumours, LOH was present in four of
25 (16%) mucinous cancer and 12 of 29 (41%) non-mucinous
cancer (Table 3).
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
M           1             2             3             4             5             6
M         1         2         3         4
M          1          2          3         4          5          6         7          8
C
B
A
Figure 2 Methylation of hMLH1 promoter determined by COBRA. (A)
DNA of C1a, RKO, Lovo, VACO432, VACO481 and VACO457 (lanes
1–6, respectively) was treated with NaHSO3, ampliﬁed by PCR, digested
with BstUI, and separated on a 2% agarose gel. The ratio of the digested
fragments (91 and 287 bp) to the total of the digested and undigested
fragment (378 bp) represents the per cent of methylation at BstUI site.
The per cents of methylation in C1a, RKO, Lovo, VACO432, VACO481
and VACO457 are 95, 95, 0, 98, 0 and 0%, respectively. M, markers. (B)
DNA from normal mucosa (lanes 1 and 3) and tumour (lanes 2 and 4)
of two colorectal cancer patients C61 (lanes 1 and 2) and C64 (lanes 3
and 4) was used for methylation analysis in the proximal region. C61
tumour shows no methylation and C64 tumour shows complete methyla-
tion at BstUI site in hMLH1 promoter. M, markers. (C) DNA from normal
mucosa (lanes 1, 2, 5, 6) and tumours (lanes 3, 4, 7, 8) of two colorectal
cancer patients C61 (lanes 1–4) and C64 (lanes 5–8) was analysed for
methylation in the distal region. The undigested products and BstUI
digested products are shown in lanes 1, 3, 5, 7 and lanes 2, 4, 6, 8, respec-
tively. M, markers.
Table 2 Colorectal carcinoma cell lines grouped in different hMLH1 and
LOH status
LOH at hMLH1 locus
7 +
Normal hMLH1
Mutation7 Expression+ Methylation7 HCT8 SW1116
Colo320DM Colo201
RW2982 RW7213
VACO411 H498
VACO10P
CACO2
SW1463
HRT18
HT29
SW620
LS123
VACO481
Lovo
Abnormal hMLH1
Mutation+ Expression+ Methylation7 LS174T
HCT116
Mutation7 Expression7 Methylation+ SW48
VACO5
VACO6
RKO
C
VACO432
Mutation+ Expression7 Methylation+ C1a
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In previous studies, researchers measured methylation in two distal
regions of hMLH1 promoter by the methods of HpaII digestion or
methylation speciﬁc PCR. Even though methylation determined in
these regions was generally consistent with the loss of gene expres-
sion, there were exceptions, and partial methylation was observed
in some MSS cell lines with normal hMLH1 expression (Deng et
al, 1999; Wheeler et al, 1999). When we utilised NaHSO3-sequen-
cing method to measure the methylation status in the whole
hMLH1promoter region, we localised a proximal region in the
promoter in which the methylation was invariably correlated to
the loss of expression. We also observed that methylation was
present in the distal region in all cell lines regardless of the expres-
sion level (Deng et al, 1999). Thus, in the present study, we
decided to analyse methylation in both the proximal region and
the distal region of hMLH1 promoter in primary colorectal cancers.
We used a simpler method (COBRA) to analyse methylation. Our
results indicated that in primary tumours, methylation of CpG sites
in the proximal region of hMLH1 promoter is correlated with the
loss of gene expression, while methylation is present in the distal
region in all tissues tested, including normal mucosa and tumours
which express hMLH1. The localization of methylation in hMLH1
promoter could help to analyse methylation status more accurately
in samples from cancer patients. For example, Markowitz et al
detected methylation in the proximal region in three serum
samples from nine colorectal cancer patients who had the same
methylation in their tumours (Grady et al, 2001). This assay
offered a potential mean for monitoring the treatment of colorectal
cancer patients with MSI.
Elucidation of the mechanisms involved in hMLH1 inactivation
is important, since this knowledge may lead to the development of
the diagnosis markers, or the ways for prevention and treatment of
colorectal cancer with MSI. LOH is considered as one of the major
mechanisms for the inactivation of tumour suppressor genes. In
the present study, we did not ﬁnd LOH in any cell lines or primary
tumours (both mucinous and non-mucinous) with abnormal
hMLH1, indicating that LOH is not a frequent mechanism of
hMLH1 inactivation in both cell lines and the primary tumours.
The inactivation of hMLH1 is mainly mediated through biallelic
methylation of the promoter or mutation of the gene. However,
LOH around hMLH1 locus was detected in four of 17 cell lines
(24%) and 16 of 54 primary tumours (30%) with normal hMLH1.
This result suggests that another unidentiﬁed tumour suppressor
gene or genes close to hMLH1 gene may exist and play a role in
colorectal carcinogenesis, especially in non-mucinous cancer with
MSS phenotype. The signiﬁcantly higher incidence of MSI in muci-
nous cancer as compared with non-mucinous cancer and higher
incidence of LOH at chromosome 3p in non-mucinous cancer with
MSS suggest different genetic aberrations and carcinogenesis in
these two histological types of colorectal cancer.
In summary, our data shows that in sporadic colorectal cancers,
methylation, but not LOH is frequently involved in hMLH1 inacti-
vation, and methylation correlates with hMLH1 gene silencing in a
region-speciﬁc manner. These observations are important not only
for understanding the MSI pathway in colorectal carcinogenesis,
but also has an important impact on the therapy of colorectal
cancer, since drug resistance can be mediated by loss of mismatch
repair, and recovering the mismatch repair function by demethyla-
tion might lead to the overcome of drug resistance (Moreland et al,
1999).
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